Authors' Affiliations: The Hormel Institute, University of Minnesota, Austin, Minnesota; Cancer Research Institute, Xiangya School of Medicine; Xiangya Hospital, Central South University, Changsha, Hunan; The First Affiliated Hospital; and Physiology and Pathophysiology, Basic Medical School, Zhengzhou University, Zhengzhou, Henan, China.
Cancer Res. 2013 Dec 1;73(23):6938-50. doi: 10.1158/0008-5472.CAN-13-0913. Epub 2013 Oct 23.
TRAF4 is an adapter protein overexpressed in certain cancers, but its contributions to tumorigenesis are unclear. In lung cancer cells and primary lung tumors, we found that TRAF4 is overexpressed. RNA interference-mediated attenuation of TRAF4 expression blunted the malignant phenotype in this setting, exerting inhibitory effects on cell proliferation, anchorage-independent growth, and tumor development in a xenograft mouse model. Unexpectedly, we discovered that TRAF4, but not Skp2, was required for activation of the pivotal cell survival kinase Akt through ubiquitination. Furthermore, TRAF4 attenuation impaired glucose metabolism by inhibiting expression of Glut1 and HK2 mediated by the Akt pathway. Overall, our work suggests that TRAF4 offers a candidate molecular target for lung cancer prevention and therapy.
TRAF4 是一种在某些癌症中过表达的衔接蛋白,但它对肿瘤发生的贡献尚不清楚。在肺癌细胞和原发性肺肿瘤中,我们发现 TRAF4 过表达。RNA 干扰介导的 TRAF4 表达衰减削弱了这种情况下的恶性表型,在异种移植小鼠模型中对细胞增殖、非锚定依赖性生长和肿瘤发展产生抑制作用。出乎意料的是,我们发现 TRAF4 而不是 Skp2 通过泛素化对于激活关键的细胞存活激酶 Akt 是必需的。此外,TRAF4 衰减通过抑制 Akt 通路介导的 Glut1 和 HK2 的表达来损害葡萄糖代谢。总的来说,我们的工作表明 TRAF4 为肺癌的预防和治疗提供了一个候选的分子靶点。